Acumen Pharmaceuticals, акция обыкновенная (US00509G2093, ABOS, ABOS.P)

Acumen Pharmaceuticals is a discovery stage biotechnology company focused on discovering and developing in partnership with leading pharmaceutical companies best in class therapeutics and diagnostics for Alzheimer's disease. Acumen owns or has exclusive license to a broad set of patents, related intellectual property and drug development capabilities relating to amyloid beta soluble oligomers, now widely believed to be an underlying cause of Alzheimer's disease. Acumen is partnered with Merck & Co. for the development of certain monoclonal antibody therapeutics. NeuroVentures LLC and Biotechnology Value Fund LP have made investments in the company.

• Чистая прибыль
• EBITDA
• Активы
• Капитал
• Чистый долг / EBITDA
• Общий долг / Капитал
• Выручка
• Рентабельность по EBITDA (%)